Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
RXII's Cash to Debt is ranked higher than
78% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 49.71 vs. RXII: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RXII' s Cash to Debt Range Over the Past 10 Years
Min: 0.35  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.85
RXII's Equity to Asset is ranked higher than
75% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. RXII: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
RXII' s Equity to Asset Range Over the Past 10 Years
Min: -1.04  Med: 0.39 Max: 0.85
Current: 0.85
-1.04
0.85
Interest Coverage No Debt
RXII's Interest Coverage is ranked higher than
68% of the 367 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RXII: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RXII' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: 9999.99
Current: No Debt
N/A
9999.99
F-Score: 3
Z-Score: -6.10
M-Score: -5.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -95360.00
RXII's Operating margin (%) is ranked lower than
98% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -73.78 vs. RXII: -95360.00 )
Ranked among companies with meaningful Operating margin (%) only.
RXII' s Operating margin (%) Range Over the Past 10 Years
Min: -30108.82  Med: -12903.64 Max: -5250.38
Current: -95360
-30108.82
-5250.38
Net-margin (%) -95090.00
RXII's Net-margin (%) is ranked lower than
98% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. RXII: -95090.00 )
Ranked among companies with meaningful Net-margin (%) only.
RXII' s Net-margin (%) Range Over the Past 10 Years
Min: -30067.65  Med: -12836.36 Max: -5244.36
Current: -95090
-30067.65
-5244.36
ROE (%) -112.06
RXII's ROE (%) is ranked lower than
84% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -32.24 vs. RXII: -112.06 )
Ranked among companies with meaningful ROE (%) only.
RXII' s ROE (%) Range Over the Past 10 Years
Min: -336.41  Med: -257.87 Max: -179.32
Current: -112.06
-336.41
-179.32
ROA (%) -87.80
RXII's ROA (%) is ranked lower than
85% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. RXII: -87.80 )
Ranked among companies with meaningful ROA (%) only.
RXII' s ROA (%) Range Over the Past 10 Years
Min: -603.25  Med: -203.85 Max: -72.95
Current: -87.8
-603.25
-72.95
ROC (Joel Greenblatt) (%) -5779.39
RXII's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. RXII: -5779.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RXII' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11172.8  Med: -4903.33 Max: -3597.18
Current: -5779.39
-11172.8
-3597.18
» RXII's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

RXII Guru Trades in Q2 2015

Jim Simons 507,000 sh (+2291.51%)
» More
Q3 2015

RXII Guru Trades in Q3 2015

Jim Simons 580,000 sh (+14.40%)
» More
Q4 2015

RXII Guru Trades in Q4 2015

Jim Simons 778,800 sh (+34.28%)
» More
Q1 2016

RXII Guru Trades in Q1 2016

Jim Simons 950,900 sh (-87.79%)
» More
» Details

Insider Trades

Latest Guru Trades with RXII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CLRB, NAS:GNVC, OTCPK:CRRTF, OTCPK:BIMUF, AMEX:APHB, OTCPK:BRTX, OTCPK:DMCAF, OTCPK:OBMP, OTCPK:PPCH, OTCPK:PKTX, OTCPK:CVALF, NAS:XTLB, NAS:RTTR, NAS:BVXV, OTCPK:ARNI, OTCPK:BCTXF, NAS:BSTG, NAS:NEOT, NAS:ONTX, NAS:KTOV » details
Traded in other countries:44R1.Germany,
RXi Pharmaceuticals Corp is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs, in the areas of dermatology and ophthalmology.

RXi Pharmaceuticals Corp was incorporated in Delaware on September 8, 2011. It is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs, in the areas of dermatology and ophthalmology. Its development programs are based on siRNA technology and immunotherapy agents. The clinical development programs include, but are not limited to, its proprietary, self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring and an immunodulating agent, Samcyprone, for the treatment of such disorders as alopecia areata, warts and cutaneous metastases of melanoma. In addition to these clinical programs, the Company has a pipeline of discovery and preclinical product candidates in its core therapeutic areas, as well as in other areas of interest. The Company's pipeline, coupled with its extensive patent portfolio, provides for the advancement to further discover and develops therapies either on its own or in collaboration with strategic partners. The Company's first clinical product candidate is RXI-109, a self-delivering RNAi compound being developed for the reduction of dermal scar formation. RXI-109 is designed to reduce the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin. RXI-109 is being developed to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. The Company competes with Alnylam Pharmaceuticals, Inc., Benitec Limited, Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Dicerna Pharmaceuticals, Inc., Sylentis, S.A. and Roche Innovation Center Copenhagen A/S. The Company is subject to federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.

Ratios

vs
industry
vs
history
P/B 2.71
RXII's P/B is ranked higher than
71% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 3.34 vs. RXII: 2.71 )
Ranked among companies with meaningful P/B only.
RXII' s P/B Range Over the Past 10 Years
Min: 1.64  Med: 8.36 Max: 50.29
Current: 2.71
1.64
50.29
P/S 1450.00
RXII's P/S is ranked lower than
96% of the 799 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. RXII: 1450.00 )
Ranked among companies with meaningful P/S only.
RXII' s P/S Range Over the Past 10 Years
Min: 64.67  Med: 190.26 Max: 1450
Current: 1450
64.67
1450
EV-to-EBIT -1.19
RXII's EV-to-EBIT is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 21.76 vs. RXII: -1.19 )
Ranked among companies with meaningful EV-to-EBIT only.
RXII' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.7  Med: -1.40 Max: -0.2
Current: -1.19
-7.7
-0.2
EV-to-EBITDA -1.19
RXII's EV-to-EBITDA is ranked lower than
99.99% of the 305 Companies
in the Global Biotechnology industry.

( Industry Median: 18.58 vs. RXII: -1.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
RXII' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.8  Med: -1.40 Max: -0.2
Current: -1.19
-7.8
-0.2
Current Ratio 6.56
RXII's Current Ratio is ranked higher than
62% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. RXII: 6.56 )
Ranked among companies with meaningful Current Ratio only.
RXII' s Current Ratio Range Over the Past 10 Years
Min: 0.48  Med: 6.92 Max: 11.98
Current: 6.56
0.48
11.98
Quick Ratio 6.56
RXII's Quick Ratio is ranked higher than
64% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. RXII: 6.56 )
Ranked among companies with meaningful Quick Ratio only.
RXII' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 6.92 Max: 11.98
Current: 6.56
0.48
11.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.93
RXII's Price/Net Cash is ranked higher than
81% of the 691 Companies
in the Global Biotechnology industry.

( Industry Median: 4.99 vs. RXII: 2.93 )
Ranked among companies with meaningful Price/Net Cash only.
RXII' s Price/Net Cash Range Over the Past 10 Years
Min: 2.32  Med: 7.80 Max: 17.2
Current: 2.93
2.32
17.2
Price/Net Current Asset Value 2.79
RXII's Price/Net Current Asset Value is ranked higher than
83% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. RXII: 2.79 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RXII' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.22  Med: 10.73 Max: 40.28
Current: 2.79
2.22
40.28
Price/Tangible Book 2.71
RXII's Price/Tangible Book is ranked higher than
76% of the 945 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. RXII: 2.71 )
Ranked among companies with meaningful Price/Tangible Book only.
RXII' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.18  Med: 10.22 Max: 35.79
Current: 2.71
2.18
35.79
Price/Median PS Value 7.63
RXII's Price/Median PS Value is ranked lower than
94% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. RXII: 7.63 )
Ranked among companies with meaningful Price/Median PS Value only.
RXII' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 0.93 Max: 7.11
Current: 7.63
0.39
7.11
Earnings Yield (Greenblatt) (%) -84.29
RXII's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 1100 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. RXII: -84.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RXII' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1264.67  Med: 196.50 Max: 3918.01
Current: -84.29
-1264.67
3918.01

More Statistics

Revenue (TTM) (Mil) $0.01
EPS (TTM) $ -1.64
Beta0.93
Short Percentage of Float2.02%
52-Week Range $1.26 - 6.49
Shares Outstanding (Mil)6.53

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -1.51 -1.43 -0.75
EPS w/o NRI ($) -1.51 -1.43 -0.75
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for RXII

Headlines

Articles On GuruFocus.com
Looking Ahead of Wall Street: RXI Pharmaceuticals, Titan Pharmaceuticals, Micron Technologies Mar 30 2015 
RXi Pharmaceuticals Corp. (RXII) CEO Noah D Beerman buys 10,000 Shares Jul 12 2010 

More From Other Websites
RXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 Jun 06 2016
RXI PHARMACEUTICALS CORP Financials May 20 2016
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition,... May 12 2016
Q1 2016 Rxi Pharmaceuticals Corp Earnings Release - After Market Close May 12 2016
RXI PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report May 12 2016
RXi Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Corporate... May 12 2016
RXi Pharmaceuticals Provides Strategic Update May 10 2016
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Other Events May 04 2016
RXi Pharmaceuticals to Present an Update on its Consumer Health Programs at the Society for... May 04 2016
RXi Pharmaceuticals and Thera Neuropharma Enter into an Exclusive License Agreement for RXi's... May 03 2016
RXi Pharmaceuticals Secures European Patent for Novel RNAi Platform May 02 2016
RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical... Apr 28 2016
RXi Pharmaceuticals to Webcast First Quarter 2016 Financial Results on Thursday, May 12, 2016 Apr 27 2016
RXi Pharmaceuticals Announces 'Biotech Spotlight' Presentation at the BioNetwork Partnering Summit Apr 26 2016
RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics... Apr 25 2016
RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead... Apr 19 2016
RXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2016... Apr 18 2016
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Material Modification to Rights of Security Holders,... Apr 15 2016
RXi Pharmaceuticals Announces Reverse Stock Split Apr 15 2016
RXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: 2015 By the Numbers Apr 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)